Navigation Links
Researchers find new target for stopping tumors developing their own blood supply
Date:11/18/2010

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

Results from a phase I clinical study of ACE-041 were presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Friday). The drug targets a receptor known as activin receptor-like kinase-1 (ALK-1), which regulates the formation of new networks of blood vessels needed for tumour growth a process known as angiogenesis. While existing anti-angiogenic drugs such as bevacizumab, sunitinib and sorafenib target other angiogenesis receptors such as VEGF, ACE-041 is one of the first to target the ALK-1 pathway.

Professor Sunil Sharma, the Jon and Karen Huntsman Presidential Professor of Cancer Research at the Huntsman Cancer Institute, University of Utah, Salt Lake City (USA), told the meeting that the connection of ALK-1 with angiogenesis was made with the discovery that mutations in the ALK-1 gene caused a condition known as hereditary haemorrhagic telangiectasia 2 (HHT2), which is characterised by impaired formation of capillary beds and causes red markings on the skin.

Acceleron Pharma, a biotechnology company in Cambridge, Massachusetts (USA), designed ACE-041 to inhibit ALK-1 signalling and asked Prof Sharma to be one of the investigators to conduct the first-in-man phase I clinical trial of the drug to see if it would inhibit tumour angiogenesis.

"Since ALK-1 is only transiently expressed on proliferating endothelial cells (the cells that line the inner surface of blood vessels), in contrast to the VEGF receptors which are constitutively expressed on endothelial and other cells, it may be a more selective target for the inhibition of angiogenesis," said Prof Sharma. "ALK-1 expression on tumour vasculature has been noted on tumour biopsy samples from a wide range of tumour types."

The phase I study enrolled patients with a range of advanced solid tumours that had spread to other parts of the body or that were inoperable, such as multiple myeloma, non-small cell lung cancer (NSCLC), head and neck cancers and carcinoid tumours (carcinoma-like neuroendocrine tumours that typically originate in the small intestine or appendix). Most patients had been treated unsuccessfully with a range of other treatments, including anti-VEGF drugs, before joining the trial. They were treated as out-patients and ACE-041 was given via subcutaneous injection.

"As of early September, 25 patients have been enrolled in the study, and we have escalated from the starting ACE-041 dose level of 0.1 mg/kg up to 4.8 mg/kg. One patient with head and neck cancer had a partial response, three patients have had stable disease and several other patients have had strongly positive responses as shown by FDG-PET scans. So far, ACE-041 has been well tolerated, with the most common adverse events being peripheral oedema, fatigue, anaemia, headache and nausea," said Prof Sharma.

"It has been very encouraging to see so many signals of efficacy in this trial, in particular because of the study population. These are end-stage cancer patients, who have already been treated with and become refractory to multiple lines of standard therapy. It has also been encouraging to see signals of ACE-041 activity in a wide range of tumour types, since this aligns with our hypothesis that ACE-041 may have anti-tumour activity in any tumour that has angiogenic activity, regardless of tumour histology. It is also important to note that while we have demonstrated significant activity with ACE-041 monotherapy in this study, we might expect to see even more efficacy in future studies with ACE-041 used in combination with other therapies."

Prof Sharma and his colleagues are planning further investigations of the safety and tolerability of the drug in an additional group of patients and hope to start phase II studies of ACE-041 in 2011.

"The anti-VEGF angiogenesis inhibitors, including bevacizumab, sunitinib and sorafenib, have been an important addition to the armamentarium of anti-cancer therapies," said Prof Sharma. "However, their efficacy is somewhat limited since tumours eventually develop the ability to stimulate angiogenesis with non-VEGF angiogenic factors. They also have serious side-effects that arise from effects on blood vessels in normal tissues. Since ACE-041 inhibits angiogenesis in a completely different way, it may have synergistic efficacy with VEGF-inhibitors, and be effective in patients who have developed resistance to VEGF-inhibitors."


'/>"/>

Contact: Emma Mason
wordmason@mac.om
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Researchers identify PTSD measures for use in traumatic brain injury research
2. New insight into the cause of common dementia found by researchers at Mayo Clinic
3. Researchers fight Americas other drug problem
4. Researchers map the way to personalised treatment for ovarian cancer
5. Four NYU researchers receive New York Academy of Sciences 2010 Young Scientists awards
6. AAPS presents awards to exemplary researchers
7. Yerkes researchers present at 40th Annual Society for Neuroscience Conference
8. Researchers see ethical dilemmas of providing care in drug detention centers
9. Circuit regulating anti-diabetic actions of serotonin uncovered by UT Southwestern researchers
10. U of M researchers find learning in the visual brain
11. Researchers discover important link between adrenal gland hormone and brain in hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering a ... frequently used by professional organic farmers and nurseries according to Sales Manager Joe Steele ... fabric pots. Our goal is to offer wholesale level pricing and ultra-fast shipping for ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... ... reminds us that May is National Stroke Awareness Month. According to the Centers for ... the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes occur ... A stroke is when blood flow to the brain is blocked or when a ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ compensation claims in ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were ... Kentucky, 16th Edition , found that indemnity costs per claim and benefit delivery expenses ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th ... Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference and will ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: